Evidence map›Paper›PMID 42236475›Full record

ArticleNature communications2026

Flipping antimicrobial peptides in the exit tunnel of the bacterial ribosome.

Weiping Huang, Max J Berger, Haaris A Safdari, Dorota Klepacki, Helge Paternoga, Chetana Baliga, Daniel N Wilson, Nora Vázquez-Laslop, Alexander S Mankin

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Weiping Huang *Department for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA.
Max J Berger *Institute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany.ORCID 0009-0001-7093-9086
Haaris A SafdariInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany.ORCID 0000-0003-3533-090X
Dorota KlepackiDepartment for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA.
Helge PaternogaInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany.ORCID 0000-0001-8335-3239
Chetana BaligaDepartment for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA.ORCID 0000-0001-9876-6810
Daniel N WilsonInstitute for Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany. daniel.wilson@uni-hamburg.de.ORCID 0000-0003-3816-3828
Nora Vázquez-LaslopDepartment for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA. nvazquez@uic.edu.ORCID 0000-0003-2256-693X
Alexander S MankinDepartment for Pharmaceutical Sciences, University of Illinois, Chicago, IL, USA. shura@uic.edu.ORCID 0000-0002-3301-827X

Funding

Advancing ribosome-targeting antibacterial peptides with a unique mechanism of actionR01AI162961 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALEXANDER S MANKIN, Terry William Moore · 2022 to 2026
$3.3M
Deutsche Forschungsgemeinschaft (German Research Foundation) WI3285/12-1NIAID NIH HHS R01 AI162961
6 · The paper itself

Abstract

Proline-rich antimicrobial peptides (PrAMPs) kill bacteria by binding in the ribosomal nascent peptide exit tunnel. Type II PrAMPs bind in an orientation matching that of the nascent protein, trap the release factors and arrest ribosomes at stop codons. Conversely, Type I PrAMPs bind in an opposite orientation: their N-terminus invades the peptidyl transferase center arresting translation at start codons. Here, by mining the genome databases, we identify a number of PrAMPs with high sequence similarity to the Type II PrAMP Drosocin. Notably, many of the new PrAMPs do not stall ribosomes at stop codons, but act as Type I PrAMPs arresting translation at start codons. Structural analysis shows that such peptides bind with a Type I orientation. Minimal alterations in the peptide structure can flip the orientation of the PrAMP in the exit tunnel, switching the mechanism of translation inhibition. Altering the mode of binding and action of a PrAMP by only few mutations could be exploited by the host to combat newly emerging bacterial pathogens.

Indexed as

Antimicrobial Cationic PeptidesAntimicrobial PeptidesBacteriaRibosomesAmino Acid SequenceMolecular Sequence DataProtein BindingProtein BiosynthesisAntimicrobial Cationic PeptidesAntimicrobial Peptides

Identifiers

PMID42236475
PMCPMC13233979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.